Phospho-ALK (Tyr1507) Antibody

What is Phospho-ALK (Tyr1507) and why is it significant in research?

Phospho-ALK (Tyr1507) refers to the anaplastic lymphoma kinase (ALK) protein specifically phosphorylated at tyrosine residue 1507. This phosphorylation site holds particular significance because it lies within a consensus Shc-binding site (NPTpY) and has been demonstrated to be critical for the interaction of full-length ALK with adaptor proteins including Shc, FRS2-α, and FRS2-β .

The phosphorylation status at Tyr1507 serves as an important biomarker for ALK activation in research contexts. When ALK is activated, phosphorylation at this site can increase dramatically – up to 38.9-fold in some experimental systems . This makes it a valuable indicator for studying ALK signaling pathways that are implicated in various cancers including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer.

What applications can Phospho-ALK (Tyr1507) Antibody be used for?

Phospho-ALK (Tyr1507) Antibody can be employed in multiple research applications:

These applications allow researchers to investigate ALK activation status, signaling dynamics, and response to ALK inhibitors in various experimental systems .

How does the physical structure of ALK relate to Tyr1507 phosphorylation?

ALK is a receptor tyrosine kinase comprising an extracellular domain, a single transmembrane domain, and an intracellular kinase domain. Tyr1507 is located outside the catalytic domain in a region important for protein-protein interactions.

Within the ALK protein structure, Tyr1507 exists in a specific recognition sequence (NPTpY) that, when phosphorylated, creates a binding site for SH2 domain-containing proteins, particularly Shc adaptor proteins . This positioning is strategic for signal transduction, as it allows ALK to recruit downstream signaling molecules following activation.

Structurally distinct from activation loop phosphorylation sites (Tyr1278, Tyr1282, and Tyr1283), Tyr1507 serves more as a docking site for signaling molecules rather than directly affecting kinase activity. This makes it an important site for monitoring ALK's capacity to engage with downstream pathways rather than just its catalytic activation .

What are the best practices for detecting ALK phosphorylation at Tyr1507?

Optimal detection of ALK Tyr1507 phosphorylation requires careful attention to several methodological aspects:

Sample Preparation:

• Harvest cells/tissues rapidly and lyse immediately in buffers containing phosphatase inhibitors

• For tissue samples, minimize ischemia time to prevent dephosphorylation

• Flash-freeze samples if immediate processing is not possible

Western Blotting Protocol Optimization:

• Use fresh reducing agents in sample buffer

• Transfer proteins to low-fluorescence PVDF membranes for optimal signal

• Implement longer blocking times (1-2 hours) to reduce background

• Use primary antibody at optimized dilutions (typically 1:500-1:2000)

• Incubate at 4°C overnight for maximum sensitivity

Controls for Validation:

• Include phosphatase-treated samples as negative controls

• Use ALK inhibitor-treated samples (e.g., crizotinib at 300nM for 1 hour) as functional negative controls

• When possible, include ALK-null cells as specificity controls

Research has shown that standard SDS-PAGE with 8% gels provides optimal resolution for full-length ALK (176 kDa), while 10% gels may be better for detecting ALK fusion proteins such as NPM-ALK (80 kDa) .

How can I validate the specificity of a Phospho-ALK (Tyr1507) Antibody?

Rigorous validation of Phospho-ALK (Tyr1507) Antibody specificity is essential for reliable research outcomes. Implement the following validation approaches:

• Phosphatase Treatment: Treat sample aliquots with lambda phosphatase before immunoblotting. A specific phospho-antibody should show signal reduction or elimination in phosphatase-treated samples.

• Peptide Competition Assay: Pre-incubate the antibody with the phosphopeptide used as immunogen (synthetic peptide derived from human ALK around Tyr1507). As demonstrated in immunohistochemistry analyses, this competitive blocking should abolish positive staining .

• ALK Inhibitor Treatment: Utilize specific ALK inhibitors like crizotinib or ceritinib. Research has shown that after 1 hour of treatment with inhibitors, autophosphorylation of ALK at Tyr1507 is significantly reduced .

• Genetic Approaches: Express a mutant ALK where Tyr1507 is replaced with phenylalanine (Y1507F). Absence of signal with this mutant confirms specificity.

• Inducible Expression Systems: As described in phosphoproteomic studies, use a Tet-On inducible system to control ALK expression. Compare antibody reactivity between induced and non-induced states, which should show dramatic differences in phosphorylation levels .

These validation steps ensure that your antibody specifically recognizes the phosphorylated form of ALK at Tyr1507 and not other phosphorylation sites or non-phosphorylated epitopes.

How does phosphorylation at Tyr1507 compare to other ALK phosphorylation sites?

ALK contains multiple phosphorylation sites with distinct roles in signaling cascades and protein function:

Research indicates that different phosphorylation sites exhibit distinct temporal patterns following ALK activation. For example, while activation loop phosphorylation occurs rapidly upon stimulation, phosphorylation at other sites may follow different kinetics depending on ALK variant and cellular context .

Phosphoproteomic studies have revealed that all of these sites show significant increases in phosphorylation upon ALK activation, but the magnitude of change can differ considerably between sites, reflecting their distinct roles in ALK signaling .

What is the relationship between ALK Tyr1507 phosphorylation and downstream signaling pathways?

Phosphorylation of ALK at Tyr1507 serves as a critical molecular switch for engaging multiple downstream signaling cascades:

• Shc Adaptor Recruitment: The phosphorylated Tyr1507 residue creates a binding site for Shc adaptor proteins, which serve as platforms for assembling signaling complexes .

• RAS-MAPK Pathway Activation: Through Shc binding, ALK can activate the RAS-MAPK pathway, leading to phosphorylation of MAPK1/3 (ERK2/1). Studies have demonstrated approximately 10-fold increases in ERK phosphorylation following ALK activation .

• STAT3 Signaling: Phosphoproteomics research has identified STAT3 as a downstream target of ALK, with Tyr705 phosphorylation increasing significantly upon ALK activation. Wild-type ALK shows delayed STAT3 activation compared to oncogenic variants like ALK F1174S .

• SHP-2 (PTPN11) Pathway: ALK activation leads to approximately 10-fold higher phosphorylation at Tyr546 and Tyr584 in SHP-2, indicating direct or indirect regulation of this phosphatase .

• Cell Cycle Regulation: Research has shown that ALK inhibition leads to M phase delay, particularly in prophase/prometaphase, and increases in misaligned chromosomes, suggesting a role for ALK phosphorylation in mitotic progression .

The specific contribution of Tyr1507 phosphorylation to each of these pathways varies, but its role as a docking site for adaptor proteins makes it a critical node in transmitting ALK activation signals to diverse cellular processes.

How can Phospho-ALK (Tyr1507) Antibody be used to evaluate ALK inhibitor efficacy?

Phospho-ALK (Tyr1507) Antibody serves as a powerful tool for assessing ALK inhibitor efficacy through several experimental approaches:

Dose-Response Analysis in Cell Culture:

• Treat ALK-expressing cells with increasing concentrations of ALK inhibitors (e.g., crizotinib, ceritinib)

• Analyze Tyr1507 phosphorylation by Western blotting at different time points

• Calculate IC50 values for phosphorylation inhibition

Cell-Based ELISA for High-Throughput Screening:
The ALK Phospho-Tyr1507 Colorimetric Cell-Based ELISA provides a quantitative, high-throughput method for measuring ALK phosphorylation in intact cells. This approach allows:

• Screening of multiple compounds simultaneously

• Determination of relative inhibitor potencies

• Assessment of off-target effects

Comparative Analysis of Multiple Phosphorylation Sites:
Research has shown that different ALK inhibitors may affect phosphorylation sites with varying efficiency. For example, studies demonstrate that ceritinib induces >50% inhibition of phosphorylation at all major ALK phospho-sites at 10nM, whereas crizotinib requires higher concentrations for similar effects .

In Vivo Pharmacodynamics:
Phospho-ALK (Tyr1507) Antibody can be used with tumor biopsy samples to:

• Establish baseline phosphorylation before treatment

• Monitor on-target activity at different time points post-treatment

• Correlate phosphorylation status with tumor response

Time-Course Studies:
Examining the temporal dynamics of ALK inhibition reveals important pharmacological properties:

• Immediate effects (30-60 minutes): Direct on-target inhibition

• Intermediate effects (2-8 hours): Pathway modulation

• Long-term effects (24+ hours): Compensatory mechanisms

This multifaceted approach provides comprehensive assessment of ALK inhibitor efficacy and mechanism of action .

What technical challenges exist when studying ALK fusion proteins with Phospho-ALK (Tyr1507) Antibody?

Researching ALK fusion proteins presents several technical challenges when using Phospho-ALK (Tyr1507) Antibody:

Molecular Weight and Epitope Accessibility:

• Full-length ALK appears at ~176 kDa on Western blots

• NPM-ALK fusion appears at ~80 kDa

• EML4-ALK variants range from ~90-120 kDa depending on the specific fusion point

• These structural differences may affect epitope accessibility or antibody affinity

Equivalent Phosphorylation Site Numbering:
The amino acid numbering differs between full-length ALK and fusion proteins:

• Tyr1507 in full-length ALK corresponds to Tyr567 in NPM-ALK

• Researchers must ensure they use correct nomenclature for their specific protein variant

Baseline Phosphorylation Status:
Many ALK fusion proteins exhibit constitutive activation, resulting in high baseline phosphorylation. This can create challenges in:

• Establishing appropriate controls

• Detecting further increases in phosphorylation upon stimulation

• Quantifying inhibitor effects when starting from a high baseline

Subcellular Localization Differences:

• Full-length ALK is primarily membrane-localized

• NPM-ALK is predominantly nuclear/nucleolar

• EML4-ALK is mainly cytoplasmic

• These localization differences require optimization of fixation and permeabilization protocols for immunofluorescence or immunohistochemistry applications

Addressing these challenges requires careful experimental design, proper controls, and validation with multiple approaches to ensure accurate interpretation of results.

How does sample preparation affect the detection of ALK Tyr1507 phosphorylation?

Sample preparation critically influences the reliable detection of ALK Tyr1507 phosphorylation across various experimental platforms:

Preserving Phosphorylation Status:
Phosphorylation is highly labile and rapidly lost due to endogenous phosphatases. Research indicates that phosphorylation half-life can be minutes rather than hours in suboptimal conditions. To preserve phosphorylation:

• Harvest cells/tissues rapidly and process immediately

• Use lysis buffers containing phosphatase inhibitor cocktails (including sodium fluoride, sodium orthovanadate, and β-glycerophosphate)

• Maintain samples at 4°C during processing

• Add reducing agents fresh to buffers before use

Fixation Considerations for Microscopy and IHC:
Different fixation protocols significantly impact phospho-epitope preservation:

• Paraformaldehyde (4%, 10-15 minutes) preserves most phospho-epitopes while maintaining structural integrity

• Methanol fixation (-20°C, 10 minutes) can preserve some phospho-epitopes but may disrupt membrane structures

• For FFPE tissues, phospho-ALK detection requires optimized antigen retrieval (typically heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0)

Quantification Considerations:
For accurate quantification of phosphorylation levels:

• Normalize phospho-ALK signal to total ALK expression

• Include internal loading controls (β-actin, GAPDH)

• Consider the dynamic range of detection methods (Western blot vs. ELISA)

• Use technical replicates to account for variation in signal intensity

Storage Effects:
Research has shown that:

• Flash-frozen samples maintain phosphorylation for several months at -80°C

• FFPE samples show gradual loss of phospho-epitopes over time (particularly in blocks stored >5 years)

• Cell lysates should be aliquoted to avoid freeze-thaw cycles, which significantly reduce phosphorylation signal

Implementing these sample preparation considerations ensures optimal detection sensitivity and reproducibility when studying ALK Tyr1507 phosphorylation.

What are potential sources of data misinterpretation when studying ALK phosphorylation at Tyr1507?

Several factors can lead to misinterpretation of data when studying ALK phosphorylation at Tyr1507:

Antibody Cross-Reactivity Issues:

• Some phospho-specific antibodies may recognize similar phosphorylation motifs in other proteins

• Cross-reactivity with other ALK phosphorylation sites (particularly Tyr1586, which has sequence similarities) can occur

• Validation using peptide competition and phosphatase treatment is essential to confirm specificity

Context-Dependent Phosphorylation Changes:
Research has shown that phosphorylation at Tyr1507 can be affected by:

• Cell confluence (decreased in highly confluent cultures)

• Serum starvation (can alter baseline phosphorylation)

• Cell cycle phase (phosphorylation varies during mitosis)

These contextual variations must be controlled to avoid misattributing changes to experimental treatments.

Technical Artifacts in Phosphorylation Detection:

• Incomplete transfer of high molecular weight proteins in Western blotting

• Epitope masking due to protein interactions or conformational changes

• Non-linear relationship between signal intensity and protein abundance at high expression levels

Misinterpretation of ALK Inhibitor Effects:
Studies have demonstrated that:

• Some effects attributed to ALK inhibition might be due to off-target activity

• Different ALK inhibitors (e.g., crizotinib vs. ceritinib) have distinct inhibition profiles

• Inhibitor effects on ALK phosphorylation may not directly correlate with functional outcomes

Fusion Protein Considerations:

• Numbering discrepancies between full-length ALK and fusion proteins (Tyr1507 in full-length corresponds to different positions in fusion proteins)

• Different baseline phosphorylation in constitutively active fusion proteins

• Altered signaling dynamics in fusion contexts

Awareness of these potential pitfalls and implementation of appropriate controls helps ensure accurate interpretation of ALK phosphorylation data.

How does ALK Tyr1507 phosphorylation relate to cell cycle regulation?

Emerging research has revealed intriguing connections between ALK Tyr1507 phosphorylation and cell cycle regulation, particularly during mitosis:

M Phase Progression:
Studies examining ALK inhibition show that active ALK is required for normal mitotic progression. When ALK is inhibited (confirmed by reduced Tyr1507 phosphorylation), cells exhibit:

• Significant delay in prophase/prometaphase

• Increased frequency of misaligned chromosomes

• No significant change in mitotic index, suggesting the delay occurs after mitotic entry

These findings indicate that ALK phosphorylation, including at Tyr1507, plays a specific role in early mitotic events rather than cell cycle entry.

Molecular Mechanisms:
The precise molecular pathways connecting ALK Tyr1507 phosphorylation to mitotic regulation remain under investigation, but research suggests several possibilities:

• Regulation of microtubule dynamics during spindle formation

• Influence on chromosome congression through kinetochore-microtubule attachments

• Potential involvement in spindle assembly checkpoint signaling

Therapeutic Implications:
Understanding the relationship between ALK phosphorylation and cell cycle has important implications for combination therapy approaches:

• ALK inhibitors combined with mitotic inhibitors may show synergistic effects

• Cell cycle phase-specific drug scheduling could enhance therapeutic efficacy

• ALK inhibitor resistance mechanisms may involve alterations in cell cycle regulation pathways

This emerging area represents an important frontier in ALK research, potentially revealing new therapeutic vulnerabilities in ALK-dependent cancers.

What are the latest advances in phosphoproteomics for studying ALK signaling networks?

Recent advances in phosphoproteomics have revolutionized our understanding of ALK signaling networks and the role of specific phosphorylation sites like Tyr1507:

Integrated Multi-Omics Approaches:
Cutting-edge research has combined phosphoproteomics with crosslinking interactome analysis to systematically identify ALK substrates. This integrated approach has:

• Identified 37 phosphotyrosine sites as ALK substrate candidates

• Created custom "kinase-substrate relationships" (KSR) datasets that improve prediction of ALK activity

• Validated findings using clinical specimens from EML4-ALK-positive patients

Temporal Dynamics Analysis:
Time-course phosphoproteomic analyses have revealed the sequence of phosphorylation events following ALK activation:

• Quantification of 655 phosphotyrosine sites

• Identification of 111 sites upregulated >1.5-fold at various time points after ALK induction

• Characterization of early, intermediate, and late phosphorylation events

Single-Cell Phosphoproteomic Approaches:
Emerging technologies allow examination of ALK signaling heterogeneity at the single-cell level, revealing:

• Cell-to-cell variability in ALK phosphorylation status

• Distinct subpopulations with differential response to ALK inhibitors

• Identification of resistance-associated phosphorylation signatures

Functional Annotation of the ALK Phosphoproteome:
Recent studies have expanded our understanding of phosphorylation sites on ALK itself:

• Full-length ALK contains at least 11 phosphotyrosine sites that show significant increases upon activation

• Phosphorylation at these sites follows distinct temporal patterns

• Computational modeling of phosphorylation networks helps predict functional outcomes of ALK activation

These advanced phosphoproteomic approaches continue to refine our understanding of ALK signaling networks and may identify novel therapeutic targets and biomarkers.